Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have advanced liposarcoma or leiomyosarcoma that has metastasized (spread)~* Have a pathology specimen available for centralized review~* Have progressive or relapsed (reappearance of) disease, received treatment with anthracycline and/or ifosfamide before enrollment in study, and have at least one measurable tumor lesion~* Have adequate bone marrow, liver and kidney function~* Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion Criteria:~* Previous exposure to Yondelis i.v. formulation, ET-743 (ecteinascidin)~* Cancer that has metastasized (spread) to the central nervous system~* Active viral hepatitis or chronic liver disease~* Unstable cardiac (heart) condition including congestive heart failure or angina pectoris (heart pain), myocardial infarction (heart attack) within 1 year before enrollment~* History of another neoplastic (malignant or nonmalignant tumor) disease (except basal cell carcinoma or cervical carcinoma adequately treated), unless in remission for 5 years or more before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yondelis weekly schedule (Type: EXPERIMENTAL): Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
- Yondelis once every 3 weeks schedule (Type: EXPERIMENTAL): Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).